Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study suggested an effective application of pattern recognition, which figured the possible biological function of potential bio-markers of rectal cancer found in our study based on their chemical structures. Hence, this study identified the precursor protein and metabolic mechanism of these bio-markers and may contribute to the neoadjuvant chemoradiation of locally advanced rectal cancer
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| TRG | Tumor regression grade | Surgery scheduled 6-8 weeks after the end of chemoradiation |
| Measure | Description | Time Frame |
|---|---|---|
| Pathologic Complete Response | Surgery scheduled 6-8 weeks after the end of chemoradiation | |
| Local Control rate | Number of participants with pelvic failure after surgery, evaluated using Kaplan-Meier Curve |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Stage T3 or T4 and/or N+ rectal adenocarcinoma cancer eligible for neoadjuvant chemoradiation
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ji Zhu, MD | Contact | +86-2164175590 | leo.zhu@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cancer Hospital, Fudan University | Recruiting | Shanghai | Shanghai Municipality | 200032 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30041962 | Derived | Jia H, Shen X, Guan Y, Xu M, Tu J, Mo M, Xie L, Yuan J, Zhang Z, Cai S, Zhu J, Zhu Z. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. Radiother Oncol. 2018 Sep;128(3):548-556. doi: 10.1016/j.radonc.2018.06.022. Epub 2018 Jul 2. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
blood, plasmaļ¼serum and urine
| From date of randomization until the date of first documented pelvic failure, assessed up to 10 years |
| Disease-free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years |
| Overall Survival | From date of randomization until the date of death from any cause, assessed up to 10 years |
| Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0 | Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0 | Up to 2 years |